What is Noble Financial’s Forecast for CRDF FY2025 Earnings?

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Noble Financial issued their FY2025 earnings per share (EPS) estimates for shares of Cardiff Oncology in a research note issued on Monday, January 5th. Noble Financial analyst R. Leboyer anticipates that the company will post earnings of ($0.76) per share for the year. Noble Financial has a “Outperform” rating and a $12.00 price objective on the stock. The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.99) per share. Noble Financial also issued estimates for Cardiff Oncology’s FY2026 earnings at ($0.82) EPS, FY2027 earnings at ($0.91) EPS and FY2030 earnings at $2.30 EPS.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardiff Oncology in a research report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $11.13.

Cardiff Oncology Price Performance

Shares of NASDAQ CRDF opened at $3.21 on Tuesday. The company’s 50 day simple moving average is $2.43 and its 200 day simple moving average is $2.59. Cardiff Oncology has a fifty-two week low of $1.90 and a fifty-two week high of $4.99. The firm has a market capitalization of $216.23 million, a P/E ratio of -4.06 and a beta of 1.40.

Cardiff Oncology (NASDAQ:CRDF) last issued its earnings results on Thursday, November 6th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.03. Cardiff Oncology had a negative net margin of 10,064.27% and a negative return on equity of 77.21%. The company had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.12 million.

Hedge Funds Weigh In On Cardiff Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Blair William & Co. IL grew its holdings in shares of Cardiff Oncology by 44.1% in the 2nd quarter. Blair William & Co. IL now owns 2,524,118 shares of the company’s stock valued at $7,951,000 after buying an additional 772,844 shares during the period. Laurion Capital Management LP lifted its holdings in Cardiff Oncology by 37.2% during the third quarter. Laurion Capital Management LP now owns 2,465,872 shares of the company’s stock worth $5,080,000 after acquiring an additional 668,590 shares in the last quarter. Acorn Capital Advisors LLC increased its holdings in shares of Cardiff Oncology by 39.3% in the third quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock worth $4,042,000 after acquiring an additional 553,317 shares in the last quarter. Flputnam Investment Management Co. increased its holdings in shares of Cardiff Oncology by 1,008.8% in the third quarter. Flputnam Investment Management Co. now owns 597,233 shares of the company’s stock worth $1,230,000 after acquiring an additional 543,370 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its position in shares of Cardiff Oncology by 183.2% during the first quarter. Jacobs Levy Equity Management Inc. now owns 396,118 shares of the company’s stock worth $1,244,000 after purchasing an additional 256,264 shares during the period. 16.29% of the stock is owned by institutional investors.

Key Cardiff Oncology News

Here are the key news stories impacting Cardiff Oncology this week:

• Positive Sentiment: Noble Financial initiated coverage with an “Outperform” rating and a $12.00 price target — a sizeable upside versus the current share price; this brokerage endorsement is the main near-term catalyst lifting the stock. Noble Financial Begins Coverage on Cardiff Oncology
• Positive Sentiment: Noble’s long-range model projects a material recovery into profitability (FY2030 EPS of $2.30 and FY2029 near break‑even), supporting the firm’s bullish valuation case if Cardiff hits clinical/commercial milestones; this gives investors a longer‑term upside thesis.
• Neutral Sentiment: Updated public financial data (cash‑flow details) are available for review — investors will want to check cash runway and burn to assess how much dilution or financing risk exists while the company pursues its programs. Cardiff Oncology Cash Flow
• Negative Sentiment: Near‑term estimates remain negative: Noble’s published quarterly and multi‑year forecasts show continued losses through FY2027 (examples: FY2025 EPS -$0.76; FY2026 EPS -$0.82; FY2027 EPS -$0.91) and quarterly EPS for 2025–2026 all negative — these projections underline ongoing cash burn and execution risk that could cap upside if milestones slip.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.